Positron emission tomography tracers in medullary thyroid carcinoma: Current evidence and emerging targets

doi:10.4329/wjr.v18.i5.120146

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 5

This Article

(21)

(18)

(0)

(36)

(456)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Radiology

ISSN

1949-8470

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Radiol. May 28, 2026; 18(5): 120146
Published online May 28, 2026. doi: 10.4329/wjr.v18.i5.120146

Table 2 Organ-specific detection sensitivities of positron emission tomography tracers in metastatic medullary thyroid carcinoma

Metastatic site	¹⁸F-FDOPA	⁶⁸Ga-SSTR	¹⁸F-FDG	¹¹C-methionine	Best performing tracer
Neck/Lymph nodes	85.7%	68.2%	61.5%	83.3%	¹⁸F-FDOPA
Liver	90.9%	75.0%	66.7%	88.9%	¹⁸F-FDOPA
Bone	84.2%	94.7%	78.9%	89.5%	⁶⁸Ga-SSTR
Lung	78.6%	71.4%	71.4%	92.9%	¹¹C-methionine

This table, based on the network meta-analysis by Li et al[10], provides a clear comparison of which tracer performs best for specific metastatic sites. ¹¹C-methionine has limited clinical availability. ¹⁸F-FDOPA: ¹⁸F-fluorodihydroxyphenylalanine; ¹⁸F-FDG: ¹⁸F-fluorodeoxyglucose; ⁶⁸Ga-SSTR: Gallium-68-labelled somatostatin receptor.

Full Size Table

Citation: Ahmed FW, Ahmed F. Positron emission tomography tracers in medullary thyroid carcinoma: Current evidence and emerging targets. World J Radiol 2026; 18(5): 120146
URL: https://www.wjgnet.com/1949-8470/full/v18/i5/120146.htm
DOI: https://dx.doi.org/10.4329/wjr.v18.i5.120146

Ahmed FW, Ahmed F. Positron emission tomography tracers in medullary thyroid carcinoma: Current evidence and emerging targets. World J Radiol 2026; 18(5): 120146 [PMID: 42238228 DOI: 10.4329/wjr.v18.i5.120146]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.